The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 24, 2016
Filed:
Oct. 13, 2014
Applicant:
Basilea Pharmaceutica Ag, Basel, CH;
Inventors:
Eric Desarbre, Mulhouse, FR;
Bérangère Gaucher, Mulhouse, FR;
Malcom G. P. Page, Basel, CH;
Patrick Roussel, Mulhouse, FR;
Assignee:
Basilea Pharmaceuticals AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4439 (2006.01); C07D 417/14 (2006.01); C07D 487/04 (2006.01); C07D 417/12 (2006.01); A61K 31/427 (2006.01); C07D 417/04 (2006.01); A61K 31/407 (2006.01); A61K 31/43 (2006.01); A61K 31/4436 (2006.01); A61K 31/545 (2006.01); A61K 31/662 (2006.01); A61K 31/69 (2006.01); A61K 45/06 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); A61K 31/41 (2006.01); A61K 31/433 (2006.01); A61K 31/4375 (2006.01); A61K 31/444 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61K 31/407 (2013.01); A61K 31/41 (2013.01); A61K 31/427 (2013.01); A61K 31/43 (2013.01); A61K 31/433 (2013.01); A61K 31/4375 (2013.01); A61K 31/444 (2013.01); A61K 31/4436 (2013.01); A61K 31/4439 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/545 (2013.01); A61K 31/662 (2013.01); A61K 31/69 (2013.01); A61K 45/06 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01);
Abstract
A pharmaceutical composition, comprising a combination of an antibiotically active compound of the formula (I): with a β-lactamase inhibitor of one of the formulae (II) to (XIII) are active against Gram-negative bacteria, in particular such bacteria which have become resistant against antibiotics such as aztreonam, carumonam and tigemonam. Optionally the compositions may comprise another β-lactamase inhibitor of one of the formulae (II) to (XIII), particularly of formula (V) or formula (VI).